[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100122139":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":35,"centralContacts":28,"locations":44,"responsibleParty":57,"collaborators":28,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":28,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":28,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":28,"overallStatus":79,"whyStopped":28,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Norgine","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"T1","EXPERIMENTAL","Pre-treatment with rifampicin",[13],"Drug: NRL972",{"label":15,"type":10,"description":16,"interventionNames":17},"T2","Pre-treatment with cyclosporin",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Reference","Administration of NRL001 alone: no pre-treatment",[13],[23,29,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","NRL972","Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1",[9],null,{"type":24,"name":25,"description":30,"armGroupLabels":31,"otherNames":28},"Reference test: Single intravenous administration of 2 mg NRL972",[19],{"type":24,"name":25,"description":33,"armGroupLabels":34,"otherNames":28},"Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972",[15],[36,40],{"name":37,"affiliation":38,"role":39},"Hans J Gruss, MD","Norgine Ltd","STUDY_DIRECTOR",{"name":41,"affiliation":42,"role":43},"Emil Gatchev, PD Dr","MHAPT \"Zaritza Johanna\" University Hospital","PRINCIPAL_INVESTIGATOR",[45],{"facility":46,"status":28,"city":47,"state":28,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":28},"Dept. Clinical Pharmacology & Therapeutics, MHAPT \"Zaritza Johanna\" University Hospital","Sofia","1527","Bulgaria","BG",{"type":52,"coordinates":53},"Point",[54,55],23.32415,42.69751,{"lat":55,"lon":54},{"type":28,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":58,"oldOrganization":5},"Vice President Clinical Development","100122139","phase-1-evaluation-of-the-pharmacokinetics-of-nrl972-following-pre-administration-of-rifampicin-and-cyclosporine-100122139",false,"NCT00856752","Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine","A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part A: Interaction With Rifampicin and Cyclosporine","Inclusion Criteria:\n\n1. Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)\n2. Caucasian\n3. Age: 21 - 40 years\n4. BW 50 - 100 kg\n5. BMI 20 - 26 kg.m-2\n6. healthy based on the pre-study examination\n7. willing and able to provide informed consent\n\nExclusion Criteria:\n\nGeneral - all subjects\n\n1. Previous participation in the trial\n2. Participant in any other trial during the last 90 days\n3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months\n4. History of any clinically relevant allergy (including hypersensitivity to the trial medications)\n5. Presence of acute or chronic infection\n6. Presence or history of any relevant co-morbidity\n7. Resting systolic blood pressure \\> 160 or \\\u003C 90 mmHg, diastolic blood pressure \\> 95 or \\\u003C 50 mmHg\n8. Clinically relevant ECG-abnormalities, prolonged QTc with \\> 450 msec in males and \\> 460 msec in females in particular\n9. Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes\n10. Positive serology for HBsAg, anti HBc and anti HCV\n11. Positive HIV test\n12. Positive alcohol or urine drug test on recruitment (and upon admission)\n13. History of alcohol and\u002For drug abuse and\u002For daily use of \\> 30 gr alcohol\n14. Smoking more than 15 cigarettes\u002Fday or equivalent of other tobacco products\n15. Use of prohibited medication\n16. Suspicion or evidence that the subject is not trustworthy and reliable\n17. Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard\n\n    General - all females\n18. Positive pregnancy test\n19. Lactating\n20. Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods \\[condom, diaphragm with spermacide gel\\] should be used in addition).",true,"ALL","21 Years","40 Years",{"count":71,"type":72},12,"ACTUAL","INTERVENTIONAL",[75],"PHASE1","A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.",[78],"Pharmacokinetics","COMPLETED","2009-03-05",{"date":82,"type":83},"2009-03-06","ESTIMATED",{"date":85,"type":28},"2006-06",{"date":87,"type":72},"2006-08",{"name":5,"class":6},1]